The 2y PFS was 57% and 45% with Ibr + Ven and Ibr + Pbo, respectively, with a consistent PFS benefit across high-risk subgroups, including those with a blastoid variant or TP53-mutated MCL. This evidence concerns the gene TP53 and mantle cell lymphoma.